156 related articles for article (PubMed ID: 30552865)
1. Ki-67 labeling index in glioblastoma; does it really matter?
Alkhaibary A; Alassiri AH; AlSufiani F; Alharbi MA
Hematol Oncol Stem Cell Ther; 2019 Jun; 12(2):82-88. PubMed ID: 30552865
[TBL] [Abstract][Full Text] [Related]
2. Prognostic relevance of NG2/CSPG4, CD44 and Ki-67 in patients with glioblastoma.
Tsidulko AY; Kazanskaya GM; Kostromskaya DV; Aidagulova SV; Kiselev RS; Volkov AM; Kobozev VV; Gaitan AS; Krivoshapkin AL; Grigorieva EV
Tumour Biol; 2017 Sep; 39(9):1010428317724282. PubMed ID: 28945172
[TBL] [Abstract][Full Text] [Related]
3. Cut-point for Ki-67 proliferation index as a prognostic marker for glioblastoma.
Wong E; Nahar N; Hau E; Varikatt W; Gebski V; Ng T; Jayamohan J; Sundaresan P
Asia Pac J Clin Oncol; 2019 Feb; 15(1):5-9. PubMed ID: 29336530
[TBL] [Abstract][Full Text] [Related]
4. Impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort.
Pollack IF; Hamilton RL; Burnham J; Holmes EJ; Finkelstein SD; Sposto R; Yates AJ; Boyett JM; Finlay JL
Neurosurgery; 2002 Jun; 50(6):1238-44; discussion 1244-5. PubMed ID: 12015841
[TBL] [Abstract][Full Text] [Related]
5. Perfusion Parameter Obtained on 3-Tesla Magnetic Resonance Imaging and the Ki-67 Labeling Index Predict the Overall Survival of Glioblastoma.
Fudaba H; Momii Y; Matsuta H; Onishi K; Kawasaki Y; Sugita K; Shimomura T; Fujiki M
World Neurosurg; 2021 May; 149():e469-e480. PubMed ID: 33567368
[TBL] [Abstract][Full Text] [Related]
6. Different assessments of immunohistochemically stained Ki-67 and hTERT in glioblastoma multiforme yield variable results: a study with reference to survival prognosis.
Persson A; Englund E
Clin Neuropathol; 2008; 27(4):224-33. PubMed ID: 18666438
[TBL] [Abstract][Full Text] [Related]
7. Impact of Multifocality and Molecular Markers on Survival of Glioblastoma.
Ahmadipour Y; Jabbarli R; Gembruch O; Pierscianek D; Darkwah Oppong M; Dammann P; Wrede K; Özkan N; Müller O; Sure U; El Hindy N
World Neurosurg; 2019 Feb; 122():e461-e466. PubMed ID: 30347300
[TBL] [Abstract][Full Text] [Related]
8. Expression of Ki-67, topoisomerase IIalpha and c-MYC in astrocytic tumors: correlation with the histopathological grade and proliferative status.
Faria MH; Gonçalves BP; do Patrocínio RM; de Moraes-Filho MO; Rabenhorst SH
Neuropathology; 2006 Dec; 26(6):519-27. PubMed ID: 17203587
[TBL] [Abstract][Full Text] [Related]
9. Is Ki-67 index overexpression in IDH wild type glioblastoma a predictor of shorter Progression Free survival? A clinical and Molecular analytic investigation.
Armocida D; Frati A; Salvati M; Santoro A; Pesce A
Clin Neurol Neurosurg; 2020 Nov; 198():106126. PubMed ID: 32861131
[TBL] [Abstract][Full Text] [Related]
10. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
11. Association between Ki-67 Labeling index and Histopathological Grading of Glioma in Indonesian Population.
Theresia E; Malueka RG; Pranacipta S; Kameswari B; Dananjoyo K; Asmedi A; Wicaksono AS; Hartanto RA; Dwianingsih EK
Asian Pac J Cancer Prev; 2020 Apr; 21(4):1063-1068. PubMed ID: 32334471
[TBL] [Abstract][Full Text] [Related]
12. Ki-67 Proliferative Activity in the Tumor Margins as a Robust Prognosis Factor in Glioblastoma Patients.
Tejada S; Becerra-Castro MV; Nuñez-Cordoba J; Díez-Valle R
J Neurol Surg A Cent Eur Neurosurg; 2021 Jan; 82(1):53-58. PubMed ID: 33260244
[TBL] [Abstract][Full Text] [Related]
13. Prognostic relevance of p53 protein expression in glioblastoma.
Birner P; Piribauer M; Fischer I; Gatterbauer B; Marosi C; Ungersböck K; Rössler K; Budka H; Hainfellner JA
Oncol Rep; 2002; 9(4):703-7. PubMed ID: 12066196
[TBL] [Abstract][Full Text] [Related]
14. Relationship between Ki-67 labeling index and survival in high-grade glioma patients treated after surgery with tamoxifen.
Mastronardi L; Guiducci A; Puzzilli F; Ruggeri A
J Neurosurg Sci; 1999 Dec; 43(4):263-70. PubMed ID: 10864388
[TBL] [Abstract][Full Text] [Related]
15. The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma.
Stark AM; Doukas A; Hugo HH; Mehdorn HM
Neurol Res; 2010 Oct; 32(8):816-20. PubMed ID: 20223108
[TBL] [Abstract][Full Text] [Related]
16. Correlation of Ki-67 Index with Volumetric Segmentation and its Value as a Prognostic Marker in Glioblastoma.
Henker C; Kriesen T; Schneider B; Glass Ä; Scherer M; Langner S; Erbersdobler A; Piek J
World Neurosurg; 2019 May; 125():e1093-e1103. PubMed ID: 30790732
[TBL] [Abstract][Full Text] [Related]
17. High expression of DNA topoisomerase IIalpha and Ki-67 antigen is associated with prolonged survival in glioblastoma patients.
Bredel M; Piribauer M; Marosi C; Birner P; Gatterbauer B; Fischer I; Ströbel T; Rössler K; Budka H; Hainfellner JA
Eur J Cancer; 2002 Jul; 38(10):1343-7. PubMed ID: 12091064
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of metallothionein in astrocytic tumors in relation to tumor grade, proliferative potential, and survival.
Hiura T; Khalid H; Yamashita H; Tokunaga Y; Yasunaga A; Shibata S
Cancer; 1998 Dec; 83(11):2361-9. PubMed ID: 9840536
[TBL] [Abstract][Full Text] [Related]
19. Ki-67 labeling is correlated with the time to recurrence in primary glioblastomas.
Schröder R; Feisel KD; Ernestus RI
J Neurooncol; 2002 Jan; 56(2):127-32. PubMed ID: 11995813
[TBL] [Abstract][Full Text] [Related]
20. Quantitative investigation of nuclear morphology in glioblastomas and its relation to survival time.
Nafe R; Franz K; Schlote W; Schneider B
Clin Neuropathol; 2003; 22(3):129-36. PubMed ID: 12809355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
